Tag: PD-1 inhibitor for adenocarcinoma

Home / PD-1 inhibitor for adenocarcinoma

Categories

Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma

The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on November 16, 2023. This approval is for the ini...
pd-1-inhibitor-for-adenocarcinoma

Scan the code